Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Debt (2016 - 2021)

Lineage Cell Therapeutics' Total Debt history spans 6 years, with the latest figure at $523000.0 for Q1 2021.

  • For Q1 2021, Total Debt changed N/A year-over-year to $523000.0; the TTM value through Mar 2021 reached $523000.0, changed N/A, while the annual FY2020 figure was $523000.0, N/A changed from the prior year.
  • Total Debt reached $523000.0 in Q1 2021 per LCTX's latest filing, roughly flat from $523000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $523000.0 in Q2 2020 to a low of $18000.0 in Q4 2017.
  • Average Total Debt over 3 years is $293000.0, with a median of $309000.0 recorded in 2017.
  • The largest YoY upside for Total Debt was 45.09% in 2017 against a maximum downside of 85.0% in 2017.
  • A 3-year view of Total Debt shows it stood at $18000.0 in 2017, then soared by 2805.56% to $523000.0 in 2020, then changed by 0.0% to $523000.0 in 2021.
  • Per Business Quant, the three most recent readings for LCTX's Total Debt are $523000.0 (Q1 2021), $523000.0 (Q4 2020), and $523000.0 (Q3 2020).